We are analyzing https://link.springer.com/article/10.1007/s00262-008-0523-4.

Title:
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy | Cancer Immunology, Immunotherapy
Description:
Abnormal accumulation of myeloid-derived suppressor cells (MDSC) is an important mechanism of tumor immune evasion. Cyclophosphamide (CTX) has also been shown in non-tumor bearing animals to cause transient surges in MDSC. Knowledge of MDSC is primarily based on preclinical work, and to date only few published studies have involved cancer patients. The goal of this study was to test the hypothesis that circulating MDSC levels correlate with clinical cancer stage, CTX-based chemotherapy, and metastatic tumor burden. Whole blood was collected from 106 newly diagnosed solid tumor patients (stages I–IV). Percentages of circulating MDSC (Lin−/Lo, HLA DR−, CD33+CD11b+) were determined prior to initiation of systemic therapy. In 17 early stage breast cancer patients receiving doxorubicin–cyclophosphamide chemotherapy every 14 days (ddAC) blood was collected on day 1 of each cycle. Circulating MDSC were significantly increased in cancer patients of all stages relative to healthy volunteers. A significant correlation between circulating MDSC and clinical cancer stage was also observed. Moreover, among stage IV patients, those with extensive metastatic tumor burden had the highest percent and absolute number of MDSC. Significant increases in circulating MDSC were observed with ddAC when compared with pretreatment levels. Circulating MDSC levels correlate with clinical cancer stage, ddAC, and metastatic tumor burden. This information must be incorporated into the design of future trials exploring immune-based therapeutic strategies. Pharmacologic modulation of MDSC should also be tested in future clinical trials.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

cancer, google, scholar, article, pubmed, cas, cells, myeloid, cell, suppressor, patients, circulating, mdsc, blood, tumor, immune, immunol, clin, myeloidderived, clinical, stage, chemotherapy, burden, gabrilovich, res, mice, privacy, cookies, content, data, increased, metastatic, cyclophosphamide, access, immature, serafini, inhibition, information, publish, research, search, correlate, salem, levels, breast, bronte, antitumor, kusmartsev, response, hollings,

Topics {✒️}

granulocyte/macrophage-colony stimulating factor-secreting myeloid-derived suppressor cells myeloid suppressor cells month download article/chapter immature myeloid cells doxorubicin–cyclophosphamide chemotherapy nitric oxide-producing cd11b ctx-based chemotherapy c-erbb-2 transgenic balb/ intergroup trial c9741/cancer article cancer immunology myeloid progenitor capable myeloid cell differentiation peroxynitrite-driven apoptotic death metastatic tumor burden full article pdf future clinical trials rethinking cancer immunotherapy mac-1+/gr-1+ cells involved cancer patients elizabeth garrett-mayer low-dose cyclophosphamide myeloid cells antitumor immune response article diaz-montero cells access cyclophosphamide-treated mice privacy choices/manage cookies clinical cancer stage antigen-specific inhibition tumor-bearing mice tumor immune evasion tumor bearing animals tumor-bearing animals node positive head dendritic cell differentiation hollings cancer center munoz-fernandez ma stage iv patients cell activation induced postoperative adjuvant treatment el-naggar sa mohamed labib salem enhanced immune response spontaneous mammary carcinomas primarily based 2/neu tolerized mice cd34+ cells cancer patients european economic area

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
         description:Abnormal accumulation of myeloid-derived suppressor cells (MDSC) is an important mechanism of tumor immune evasion. Cyclophosphamide (CTX) has also been shown in non-tumor bearing animals to cause transient surges in MDSC. Knowledge of MDSC is primarily based on preclinical work, and to date only few published studies have involved cancer patients. The goal of this study was to test the hypothesis that circulating MDSC levels correlate with clinical cancer stage, CTX-based chemotherapy, and metastatic tumor burden. Whole blood was collected from 106 newly diagnosed solid tumor patients (stages I–IV). Percentages of circulating MDSC (Lin−/Lo, HLA DR−, CD33+CD11b+) were determined prior to initiation of systemic therapy. In 17 early stage breast cancer patients receiving doxorubicin–cyclophosphamide chemotherapy every 14 days (ddAC) blood was collected on day 1 of each cycle. Circulating MDSC were significantly increased in cancer patients of all stages relative to healthy volunteers. A significant correlation between circulating MDSC and clinical cancer stage was also observed. Moreover, among stage IV patients, those with extensive metastatic tumor burden had the highest percent and absolute number of MDSC. Significant increases in circulating MDSC were observed with ddAC when compared with pretreatment levels. Circulating MDSC levels correlate with clinical cancer stage, ddAC, and metastatic tumor burden. This information must be incorporated into the design of future trials exploring immune-based therapeutic strategies. Pharmacologic modulation of MDSC should also be tested in future clinical trials.
         datePublished:2008-04-30T00:00:00Z
         dateModified:2008-04-30T00:00:00Z
         pageStart:49
         pageEnd:59
         sameAs:https://doi.org/10.1007/s00262-008-0523-4
         keywords:
            Immature myeloid cells
            Myeloid-derived suppressor cells
            Breast cancer
            Cancer
            Cyclophosphamide
            Tumor burden
            Cytokines
            PBMC
            T cells
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig7_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:58
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:C. Marcela Diaz-Montero
               affiliation:
                     name:Medical University of South Carolina, Hollings Cancer Center
                     address:
                        name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mohamed Labib Salem
               affiliation:
                     name:Medical University of South Carolina, Hollings Cancer Center
                     address:
                        name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael I. Nishimura
               affiliation:
                     name:Medical University of South Carolina, Hollings Cancer Center
                     address:
                        name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elizabeth Garrett-Mayer
               affiliation:
                     name:Medical University of South Carolina, Hollings Cancer Center
                     address:
                        name:Department of Biostatistics, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David J. Cole
               affiliation:
                     name:Medical University of South Carolina, Hollings Cancer Center
                     address:
                        name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alberto J. Montero
               affiliation:
                     name:Medical University of South Carolina, Hollings Cancer Center
                     address:
                        name:Department of Medicine, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
      description:Abnormal accumulation of myeloid-derived suppressor cells (MDSC) is an important mechanism of tumor immune evasion. Cyclophosphamide (CTX) has also been shown in non-tumor bearing animals to cause transient surges in MDSC. Knowledge of MDSC is primarily based on preclinical work, and to date only few published studies have involved cancer patients. The goal of this study was to test the hypothesis that circulating MDSC levels correlate with clinical cancer stage, CTX-based chemotherapy, and metastatic tumor burden. Whole blood was collected from 106 newly diagnosed solid tumor patients (stages I–IV). Percentages of circulating MDSC (Lin−/Lo, HLA DR−, CD33+CD11b+) were determined prior to initiation of systemic therapy. In 17 early stage breast cancer patients receiving doxorubicin–cyclophosphamide chemotherapy every 14 days (ddAC) blood was collected on day 1 of each cycle. Circulating MDSC were significantly increased in cancer patients of all stages relative to healthy volunteers. A significant correlation between circulating MDSC and clinical cancer stage was also observed. Moreover, among stage IV patients, those with extensive metastatic tumor burden had the highest percent and absolute number of MDSC. Significant increases in circulating MDSC were observed with ddAC when compared with pretreatment levels. Circulating MDSC levels correlate with clinical cancer stage, ddAC, and metastatic tumor burden. This information must be incorporated into the design of future trials exploring immune-based therapeutic strategies. Pharmacologic modulation of MDSC should also be tested in future clinical trials.
      datePublished:2008-04-30T00:00:00Z
      dateModified:2008-04-30T00:00:00Z
      pageStart:49
      pageEnd:59
      sameAs:https://doi.org/10.1007/s00262-008-0523-4
      keywords:
         Immature myeloid cells
         Myeloid-derived suppressor cells
         Breast cancer
         Cancer
         Cyclophosphamide
         Tumor burden
         Cytokines
         PBMC
         T cells
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0523-4/MediaObjects/262_2008_523_Fig7_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:58
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:C. Marcela Diaz-Montero
            affiliation:
                  name:Medical University of South Carolina, Hollings Cancer Center
                  address:
                     name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mohamed Labib Salem
            affiliation:
                  name:Medical University of South Carolina, Hollings Cancer Center
                  address:
                     name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael I. Nishimura
            affiliation:
                  name:Medical University of South Carolina, Hollings Cancer Center
                  address:
                     name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elizabeth Garrett-Mayer
            affiliation:
                  name:Medical University of South Carolina, Hollings Cancer Center
                  address:
                     name:Department of Biostatistics, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David J. Cole
            affiliation:
                  name:Medical University of South Carolina, Hollings Cancer Center
                  address:
                     name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alberto J. Montero
            affiliation:
                  name:Medical University of South Carolina, Hollings Cancer Center
                  address:
                     name:Department of Medicine, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:58
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Medical University of South Carolina, Hollings Cancer Center
      address:
         name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
         type:PostalAddress
      name:Medical University of South Carolina, Hollings Cancer Center
      address:
         name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
         type:PostalAddress
      name:Medical University of South Carolina, Hollings Cancer Center
      address:
         name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
         type:PostalAddress
      name:Medical University of South Carolina, Hollings Cancer Center
      address:
         name:Department of Biostatistics, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
         type:PostalAddress
      name:Medical University of South Carolina, Hollings Cancer Center
      address:
         name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
         type:PostalAddress
      name:Medical University of South Carolina, Hollings Cancer Center
      address:
         name:Department of Medicine, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:C. Marcela Diaz-Montero
      affiliation:
            name:Medical University of South Carolina, Hollings Cancer Center
            address:
               name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
               type:PostalAddress
            type:Organization
      name:Mohamed Labib Salem
      affiliation:
            name:Medical University of South Carolina, Hollings Cancer Center
            address:
               name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
               type:PostalAddress
            type:Organization
      name:Michael I. Nishimura
      affiliation:
            name:Medical University of South Carolina, Hollings Cancer Center
            address:
               name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
               type:PostalAddress
            type:Organization
      name:Elizabeth Garrett-Mayer
      affiliation:
            name:Medical University of South Carolina, Hollings Cancer Center
            address:
               name:Department of Biostatistics, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
               type:PostalAddress
            type:Organization
      name:David J. Cole
      affiliation:
            name:Medical University of South Carolina, Hollings Cancer Center
            address:
               name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
               type:PostalAddress
            type:Organization
      name:Alberto J. Montero
      affiliation:
            name:Medical University of South Carolina, Hollings Cancer Center
            address:
               name:Department of Medicine, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
      name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
      name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
      name:Department of Biostatistics, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
      name:Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
      name:Department of Medicine, Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(112)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.96s.

LINK . SPRINGER . COM {}